Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer
Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent

BusinessWire_EN 
0 19.02.20
Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study
Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the

BusinessWire_EN 
0 17.02.20
Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares
Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares


Regulatory News:



Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) (Paris:ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore

BusinessWire_EN 
0 13.02.20
Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares
Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore

BusinessWire_EN 
0 10.02.20
VALBIOTIS meldet weltweite strategische Partnerschaft mit NESTLÉ HEALTH SCIENCE bei der Entwicklung und Vermarktung von TOTUM-63, ein pflanzlicher Wirkstoff mit klinisch nachgewiesenem Nutzen für die Stoffwechselgesundheit bei Prädiabetes
VALBIOTIS meldet weltweite strategische Partnerschaft mit NESTLÉ HEALTH SCIENCE bei der Entwicklung und Vermarktung von TOTUM-63, ein pflanzlicher Wirkstoff mit klinisch nachgewiesenem Nutzen für die Stoffwechselgesundheit bei Prädiabetes


VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von

BusinessWire_DE 
0 06.02.20
VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics
VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics


Regulatory News:



VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic

BusinessWire_EN 
0 05.02.20
Sensorion to Attend and Present at LSX World Congress 2020
Sensorion to Attend and Present at LSX World Congress 2020


Regulatory News:



Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and

BusinessWire_EN 
0 03.02.20
Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020
Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent

BusinessWire_EN 
0 30.01.20
Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the

BusinessWire_EN 
0 10.01.20
Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 Trial for SENS-401 in Sudden Sensorineural Hearing Loss
Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 Trial for SENS-401 in Sudden Sensorineural Hearing Loss


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent

BusinessWire_EN 
0 23.12.19
Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study
Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore

BusinessWire_EN 
0 23.12.19
GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history
GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210006078/en/



Figure 1. LHON Natural History from Interim Analysis


BusinessWire_EN 
0 11.12.19
The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France
The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191208005050/en/



The National Eye Hospital (CHNO) of the Quinze-Vingt

BusinessWire_EN 
0 09.12.19
Sensorion Announces Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy
Sensorion Announces Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore

BusinessWire_EN 
0 02.12.19
Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover
Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and

BusinessWire_EN 
0 08.11.19
THERANEXUS ANNONCE LE FRANCHISSEMENT D'UNE ETAPE DE PHARMACOCINETIQUE CLINIQUE DANS LE CADRE DU DEVELOPPEMENT DE SES CANDIDATS MEDICAMENTS THN201 ET THN101
THERANEXUS ANNONCE LE FRANCHISSEMENT D'UNE ETAPE DE PHARMACOCINETIQUE CLINIQUE DANS LE CADRE DU DEVELOPPEMENT DE SES CANDIDATS MEDICAMENTS THN201 ET THN101
Lyon, le 21 mars 2018 – THERANEXUS, société biopharmaceutique innovante dans le traitement des maladies neurologiques et pionnière dans le développement de candidats médicaments jouant sur....
Actusnews 
0 21.03.18
THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101
THERANEXUS ANNOUNCES A SUCCESSFUL CLINICAL PHARMACOKINETIC STUDY AS PART OF THE DEVELOPMENT OF ITS DRUG CANDIDATES THN201 AND THN101
Lyon, 21 March 2018 – THERANEXUS, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates acting on the interaction....
Actusnews 
0 21.03.18
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE AU 28/02/2018
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE AU 28/02/2018
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Actusnews 
0 15.03.18
ALPHA MOS : CHIFFRE D'AFFAIRES ANNUEL 2017
ALPHA MOS : CHIFFRE D'AFFAIRES ANNUEL 2017
En M€ - Normes IFRS Données consolidées non auditées 2017 2016 Variation Chiffre d'affaires 4,0 7,5  -46% Alpha MOS (Euronext Paris – Compartiment C – Code ISIN :....
Actusnews 
0 16.02.18
ALPHA MOS : DEMISSION D'OLIVIER SICHEL DE SON POSTE D'ADMINISTRATEUR ALPHA MOS
ALPHA MOS : DEMISSION D'OLIVIER SICHEL DE SON POSTE D'ADMINISTRATEUR ALPHA MOS
Monsieur Olivier SICHEL, administrateur indépendant au sein du Conseil d'administration d'Alpha MOS, a informé le Conseil de sa décision de mettre un terme à ses fonctions avec effet au 19....
Actusnews 
0 29.12.17
ALPHA MOS : Informations relatives au nombre total de droits de vote
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Actusnews 
0 06.12.17
ALPHA MOS : CHIFFRE D'AFFAIRES NEUF MOIS 2017
ALPHA MOS : CHIFFRE D'AFFAIRES NEUF MOIS 2017
En M€ - Normes IFRS Données non auditées 2017 2016 Variation Chiffre d'affaires 1er semestre 2,1 3,9  -47% Chiffre d'affaires 3ème....
Actusnews 
0 27.10.17
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Actusnews 
0 13.10.17
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE
 INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Actusnews 
0 26.09.17
ALPHA MOS : COMMUNIQUE DE MISE A DISPOSITION DE LA NOTE EN REPONSE
ALPHA MOS : COMMUNIQUE DE MISE A DISPOSITION DE LA NOTE EN REPONSE
OFFRE PUBLIQUE D'ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIETE ALPHA MOS INITIEE CONJOINTEMENT PAR JOLT CAPITAL AMBROSIA INVESTMENTS PRESENTEE PAR ALANTRA COMMUNIQUE DE MISE....
Actusnews 
0 20.09.17